Company intelligence / Profile preview

Arialys Therapeutics

La Jolla, California, United Statesarialysrx.com ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Arialys has completed all five Single Ascending Dose (SAD) cohorts and initiated Multiple Ascending Dose (MAD) cohorts in its Phase 1 study of ART5803. The drug was well tolerated at all dose levels (3 mg/kg to 100 mg/kg) with no treatment-related dose reductions or serious adverse events. CSF exposures were consistent with potentially efficacious CNS levels. Phase 2 proof-of-concept studies in ANRE patients are anticipated to start in the second half of 2025.

Therapeutic areas: ImmunologyPsychiatryNeurology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

ART5803

1 more asset in the full pipeline.

Request access →

Partnerships

Nucleus Network (for clinical trials)Astellas (asset acquisition)

Beyond the preview

Go deeper on Arialys Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arialys Therapeutics.

Explore the full profile